Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial

BACKGROUND: Inhaled glucocorticoid corticosteroid (ICS), long-acting β2-adrenoceptor agonist (LABA), and other drugs have limited therapeutic effects on COPD with significant individual differences. Traditional Chinese medicine (TCM)-modified Bushen Yiqi formula (MBYF) demonstrates advantages in COP...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Qing, Cao, Yuxue, Gao, Zhen, Sun, Jing, Zhang, Hongying, Du, Yijie, Lv, Yubao, Zhou, Sihan, Tang, Zihui, Liu, Baojun, Dong, Jingcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842909/
https://www.ncbi.nlm.nih.gov/pubmed/35164853
http://dx.doi.org/10.1186/s13063-022-06057-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842909/
https://www.ncbi.nlm.nih.gov/pubmed/35164853
http://dx.doi.org/10.1186/s13063-022-06057-7

Ejemplares similares